Valuation : Structure Therapeutics Inc.

Market Cap 337.58Cr 290.49Cr 273.31Cr 249.67Cr 467.05Cr 32TCr 468.33Cr 3.23TCr 1.25TCr 16TCr 1.27TCr 1.24TCr 53TCr P/E 2026 *
-29.2x
P/E 2027 * -21.6x
Enterprise Value 240.87Cr 207.26Cr 195.01Cr 178.14Cr 333.24Cr 23TCr 334.15Cr 2.3TCr 894.19Cr 12TCr 904.47Cr 884.75Cr 38TCr EV / Sales 2026 *
62.6x
EV / Sales 2027 * 67,593x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week-0.06%
Current month+3.11%
1 month-4.63%
3 months+21.20%
6 months-25.01%
Current year-31.93%
1 week 45.1
Extreme 45.1
48.64
1 month 45.1
Extreme 45.1
55.6
Current year 35.78
Extreme 35.78
94.77
1 year 20.04
Extreme 20.04
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 01/05/2022
Chief Executive Officer 62 01/05/2019
Chief Operating Officer 49 15/04/2026
Director TitleAgeSince
Director/Board Member 62 01/02/2019
Chairman 68 19/01/2022
Director/Board Member 66 29/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/08/26 Exercice

Chief Technology Officer

43,329 0.0310%
04/08/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.06%+139.57%+61.18% 337.58Cr
-1.79%-2.27%+50.90%+89.03% 6.8TCr
-2.06%-0.18%+41.53%+88.17% 6.49TCr
-0.31%+6.54%-11.39%+457.82% 2.76TCr
-3.00%-2.90%+39.40%+9.41% 2.57TCr
+0.86%+1.65%+0.25%-14.78% 2.61TCr
-1.46%+0.42%+24.07%-18.70% 2.01TCr
-2.96%-15.21%+210.71%+370.84% 1.72TCr
-1.49%-4.88%-0.41%+530.26% 1.49TCr
-0.20%+8.37%+57.87%+159.50% 1.46TCr
Average -1.24%+0.23%+55.25%+173.27% 2.82TCr
Weighted average by Cap. -1.50%+0.17%+43.45%+144.08%

Financials

2026 *2027 *
Net sales 3.85Cr 3.31Cr 3.11Cr 2.84Cr 5.32Cr 363.14Cr 5.34Cr 37Cr 14Cr 186.31Cr 14Cr 14Cr 600.22Cr 41.67T 35.86T 33.74T 30.82T 57.65T 39.34L 57.81T 4L 2L 20.19L 2L 2L 65.03L
Net income -31Cr -27Cr -25Cr -23Cr -43Cr -2.91TCr -43Cr -295.16Cr -114.53Cr -1.49TCr -115.85Cr -113.33Cr -4.81TCr -48Cr -41Cr -38Cr -35Cr -66Cr -4.49TCr -66Cr -454.78Cr -176.47Cr -2.3TCr -178.5Cr -174.61Cr -7.42TCr
Net Debt -97Cr -83Cr -78Cr -72Cr -133.81Cr -9.13TCr -134.17Cr -925.27Cr -359.05Cr -4.69TCr -363.18Cr -355.26Cr -15TCr -56Cr -48Cr -45Cr -41Cr -77Cr -5.28TCr -78Cr -534.99Cr -207.6Cr -2.71TCr -209.99Cr -205.41Cr -8.73TCr
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
04/26/04 $47.34 0.00% 2,81,709
03/26/03 $47.34 -0.96% 6,21,486
02/26/02 $47.80 +1.42% 10,64,737
01/26/01 $47.13 +2.66% 8,16,626
31/26/31 $45.91 -3.08% 13,94,959
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
47.34USD
Average target price
104.77USD
Spread / Average Target
+121.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock